Trevi Therapeutics (TRVI) closed at $13.29 on November 16, 2026, down 2.6% from the previous close, on volume of 1,572,334 shares (30-day average 2,254,549).
Data as of November 16, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 2, 2026 | Put with Delta Hedge | 15-Jan-27 13 P +11,636 Stock | 321 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 16, 2026. See the largest for 5, 30, 60 and 90 days
Trevi Therapeutics Earnings Call Signals Broad Clinical Progress
TipRanks (Sat, 14-Nov 11:27 PM ET)
Trevi’s IPF Cough Trial Moves Forward as Phase 3 Study Recruits
TipRanks (Fri, 13-Nov 11:31 AM ET)
Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
Globe Newswire (Mon, 9-Nov 4:05 PM ET)
Globe Newswire (Mon, 2-Nov 4:05 PM ET)
Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference
Globe Newswire (Tue, 27-Oct 7:30 AM ET)
Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting
Globe Newswire (Tue, 13-Oct 7:30 AM ET)
Trevi Therapeutics to Participate in Upcoming September Conferences
Globe Newswire (Thu, 3-Sep 7:30 AM ET)
Globe Newswire (Wed, 26-Aug 7:30 AM ET)
Trevi Therapeutics Prices $150 Million Offering, Bolstering Funding for Chronic Cough Research
Market Chameleon (Fri, 17-Apr 7:47 AM ET)
Market Chameleon (Mon, 9-Mar 5:13 AM ET)
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
Trevi Therapeutics trades on the NASDAQ stock market under the symbol TRVI.
As of November 17, 2026, TRVI stock price declined to $13.12 with 411,695 million shares trading.
TRVI has a beta of 1.38, meaning it tends to be more sensitive to market movements. TRVI has a correlation of 0.10 to the broad based SPY ETF.
TRVI has a market cap of $1.87 billion. This is considered a Small Cap stock.
In the last 3 years, TRVI traded as high as $20.22 and as low as $.97.
The top ETF exchange traded funds that TRVI belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
TRVI has outperformed the market in the last year with a return of +15.4%, while the SPY ETF gained +9.9%. However, in the most recent history, TRVI shares have underperformed the stock market with its stock returning -28.9% in the last 3 month period and -3.7% for the last 2 week period, while SPY has returned -5.6% and -2.8%, respectively.
TRVI support price is $12.79 and resistance is $13.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TRVI shares will trade within this expected range on the day.